IMRX: Maldonado Reiterates Buy Rating and Maintains $14 Price Target on Encouraging Atebimetinib Survival and Phase 3 Progress
at www.tipranks.com (Fri, 30-Oct 6:35 AM)
Immuneering GAAP EPS of -$0.37 misses by $0.06
at seekingalpha.com (Thu, 29-Oct 4:51 PM)
